公开(公告)号：US20100218414A1

公开(公告)日：2010-09-02

申请号：US12733479

申请日：2008-09-04

申请人： Mladen Zinic ,  Janja Makarevic

发明人： Mladen Zinic ,  Janja Makarevic

IPC分类号： C10L7/00 ,  C07C231/02 ,  C07C237/22

CPC分类号： C07C233/56 ,  A61K8/042 ,  A61K8/44 ,  C07C231/02

摘要： The compounds of general formula (I) wherein: R1 is hydrogen, phenyl, C1-6 alkyl which can be further substituted with R3, R3 is 5- or 6-membered aromatic or heteroaromatic ring system which can be further substituted with benzyl or hydroxyl groups; R2 is OR4, NHR4, R4 is hydrogen, C1-6 alkyl or benzyl n is an integer from 1 to 12 or the salts of compounds mentioned which can form gels with commercial fuels, organic solvents and water.

摘要翻译： 通式（I）的化合物其中：R 1是氢，苯基，可以被R 3进一步取代的C 1-6烷基，R 3是可被苄基或羟基进一步取代的5-或6-元芳族或杂芳族环系 团体 R 2是OR 4，NHR 4，R 4是氢，C 1-6烷基或苄基，n是1至12的整数，或者可以与商业燃料，有机溶剂和水形成凝胶的化合物的盐。

公开(公告)号：US20110081405A1

公开(公告)日：2011-04-07

申请号：US12896447

申请日：2010-10-01

申请人： Zorka Mikloska ,  Boris Subotic ,  Mladen Zinic

发明人： Zorka Mikloska ,  Boris Subotic ,  Mladen Zinic

IPC分类号： A61K9/127 ,  C01B39/02 ,  A61K33/06 ,  A61K9/14 ,  A61P31/12

CPC分类号： A61K33/06 ,  A61K31/07 ,  A61K31/355 ,  A61K31/375 ,  A61K31/593 ,  A61K45/06 ,  A61K2300/00

摘要： Antiviral medicine (compound) presented here is comprised of an active substance, a carrier of active substance and additives, and it is used for the prophylaxis, therapy and/or pre-respectively post-treatment of diseases caused by the infection with Herpes simplex virus type 1 and/or 2.The active substance is represented by the synthetic zeolites in pure form, with defined crystal structures and chemical compositions. The active substance (zeolite) has a crystal size of 0.1-10 μm and specific surface of 400-1200 m2/g. The sodium ions can be partially or completely exchanged with other cations, e.g. K+, Ag+, NH4+, Ca2+, Mg2+, Mn2+, Zn2+, Cu2+, Fe2+ and Fe3+ in active substance of this antiviral compound.The carrier of active compound is the organic gel, water, oil, cream, liposome and liposome-based systems with regular and/or prolonged activity. The weight ratio between the active substance and the carrier is 5×10−9-10−3, i.e. 5 ng to 1 mg of active substance per one gram of the carrier. The additives used are vitamines: Vitamin C (0-20 wt. %), vitamin E (0-0.01 wt. %), vitamin A (0-1 wt. %) and vitamin D3 (0-1 wt. %).The efficacy of this preparation was demonstrated in in vitro experiments of the inhibition of HSV-1 and HSV-2 plaques formation in keratinocyte monolayers that were preincubated, coincubated or postincubated with the virus at the different time points (by up to 92%).

摘要翻译： 本文提供的抗病毒药物（化合物）由活性物质，活性物质的载体和添加剂组成，用于预防，治疗和/或预分解由单纯疱疹病毒感染引起的疾病的后处理 类型1和/或2.活性物质由纯形式的合成沸石表示，具有限定的晶体结构和化学组成。 活性物质（沸石）的结晶尺寸为0.1-10μm，比表面积为400-1200m 2 / g。 钠离子可以与其他阳离子部分或完全交换。 K +，Ag +，NH4 +，Ca2 +，Mg2 +，Mn2 +，Zn2 +，Cu2 +，Fe2 +和Fe3 +。 活性化合物的载体是具有规则和/或延长活性的有机凝胶，水，油，霜，脂质体和基于脂质体的系统。 活性物质与载体的重量比为5×10-9-10-3，即每克载体为5ng至1mg活性物质。 使用的添加剂是维生素C：维生素C（0-20重量％），维生素E（0-0.01重量％），维生素A（0-1重量％）和维生素D3（0-1重量％）。 这种制剂的功效在体外实验中表明，在不同时间点（与高达92％）相比，预处理，重合或后处理病毒的角质形成细胞单层中HSV-1和HSV-2噬菌斑形成的抑制。